One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration
| Autor: | Kyoko Hattori, Kenichi Kawano, Tadasu Sugita, Eimei Ra, Kei Takayama, Ruka Maruko, Hiroko Terasaki, Yasuki Ito, Keiko Kataoka, Hiroki Kaneko |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Time Factors genetic structures Recombinant Fusion Proteins Visual Acuity Retina 03 medical and health sciences chemistry.chemical_compound Macular Degeneration 0302 clinical medicine Pro re nata Ophthalmology Age related medicine Humans 030212 general & internal medicine Aged Retrospective Studies business.industry Aflibercept Injection General Medicine Macular degeneration medicine.disease eye diseases Sensory Systems Choroidal Neovascularization Vascular endothelial growth factor Receptors Vascular Endothelial Growth Factor Treatment Outcome chemistry Intravitreal Injections 030221 ophthalmology & optometry Optometry Female sense organs business Tomography Optical Coherence Follow-Up Studies |
| Zdroj: | Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 237(2) |
| ISSN: | 1423-0267 |
| Popis: | Purpose: We compared 1-year outcomes of 1 + pro re nata (PRN) versus 3 + PRN of intravitreal aflibercept injection (IAI) for age-related macular degeneration (AMD). Methods: Forty-two eyes with naïve AMD received 3 + PRN IAI treatment and 47 eyes with naïve AMD received 1 + PRN IAI treatment. Visual acuity (VA), central retinal thickness (CRT), and central choroidal thickness (CCT) and number of administered IAIs during 12 months were compared. Results: VAs improved, and CRTs reduced significantly at any given month from baseline in both groups (p < 0.01, respectively). CCT reduced significantly at 3 months in the 3 + PRN group (p = 0.024) but not in the 1 + PRN group. The 1 + PRN group received fewer injections than the 3 + PRN group (p < 0.01). Conclusions: Aflibercept leads to equivalent VA and morphologic retinal improvement without administering 3 injections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|